Form 4: Ultragenyx Officer Pinion Reports Stock Transactions

Ultragenyx Pharmaceutical Inc.'s EVP, Chief Quality Operations Officer, John Richard Pinion, reported the acquisition of shares from vested performance units and subsequent sale for tax obligations.

Summary

• John Richard Pinion, EVP, Chief Quality Operations Officer of Ultragenyx Pharmaceutical Inc., reported two transactions.
• On March 1, 2026, Pinion acquired 11,137 shares of common stock at a price of $0, resulting from the conversion of previously granted performance stock units (PSUs) upon certification of performance metrics.
• On March 2, 2026, Pinion sold 10,029 shares of common stock at a weighted average price of $22.80 per share to cover tax withholdings related to the vesting of restricted stock units (RSUs).
• The shares sold for tax purposes ranged in price from $22.54 to $23.11.
• Following these transactions, Pinion beneficially owns 110,026 shares of Ultragenyx common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction primarily driven by executive compensation vesting and tax obligations. The successful vesting of performance units is a minor positive, indicating achievement of internal metrics.

Positives

• The acquisition of 11,137 shares indicates the successful certification of performance metrics for previously granted performance stock units, suggesting the company met certain internal goals.
• The vesting of RSUs, which led to the tax-related sale, represents a positive compensation event for the officer.

Negatives

• The sale of 10,029 shares, while for tax purposes, reduces the officer's direct ownership in the company.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to vesting and tax withholdings, are common in the biotechnology sector as part of executive compensation packages. These routine sales typically do not signal a change in management's outlook on the company's prospects, unlike discretionary sales.

Comparison to Industry Standards

• Sales for tax withholding purposes are a standard practice across all industries, including biotechnology, when equity awards vest. The reported sale of 10,029 shares by John Richard Pinion, representing a portion of vested equity, is consistent with typical executive compensation and tax planning strategies observed at comparable biopharmaceutical companies.
• For instance, executives at companies like Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX) frequently report similar transactions following RSU or PSU vesting events.

Stakeholder Impact

• Shareholders: Minimal direct impact. The sale for tax purposes is routine and not indicative of a change in company fundamentals. The increase in shares outstanding from PSU conversion is minor.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation vesting and subsequent tax-related sales, which are common and pre-scheduled under a 10b5-1 plan. Such transactions typically do not provide new fundamental information about the company's prospects or signal a change in management's confidence. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to alter an existing investment thesis.

Keywords

Ultragenyx Pharmaceutical Inc., RARE, Form 4, Insider transaction, Stock sale, Performance stock units, Restricted stock units, Tax withholding, Executive compensation, Biotechnology